---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000047"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:26:21.857984+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand Q2 adjusted EPS $1.42 beats; raises FY2023 adjusted EPS outlook to $4.85-$5.00

## Summary
- Q2 adjusted net income from continuing ops $25.1M ($1.42 diluted) vs $7.4M ($0.43) prior year; GAAP EPS $0.13.
- Royalties grew 15% to $20.4M; core Captisol sales $5.2M vs $3.3M. No COVID-19 Captisol sales vs $26.2M.
- Cash $219M; debt-free after May 2023 convertible note payoff. $50M share repurchase program authorized.
- FY2023 guidance: revenue $124-128M (reaffirmed); adjusted EPS raised to $4.85-$5.00 from $4.60-$4.75.
- Agreed to purchase Novan assets for $15M cash plus DIP financing; Berdazimer gel NDA PDUFA Jan 5, 2024.

## SEC filing metadata
- accession: 0000886163-23-000047
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/lgnd-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000047
- JSON: https://secwatch.observer/filing/0000886163-23-000047.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000047.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue Total revenues for the six months ended June 30, 2023 were $70.3 million., net income Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted sha, EPS $2.57 per diluted share. Guidance reaffirmed.
  - Period: the six months ended June 30, 2023
  - Revenue: Total revenues for the six months ended June 30, 2023 were $70.3 million.
  - Net income: Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted sha
  - EPS: $2.57 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported the three and six months ended June 30, 2023 results: revenue Total revenues for the second quarter of 2023 were $26.4 million., net income Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share, EPS $0.13 per diluted share. Guidance reaffirmed.
  - Period: the three and six months ended June 30, 2023
  - Revenue: Total revenues for the second quarter of 2023 were $26.4 million.
  - Net income: Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share
  - EPS: $0.13 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.